investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
BLA submission based on data from Phase 1/2 and Phase 3 Northstar studies, which represent more than 220 patient-years of experience with beti-cel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of itsRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2021-- 2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy’sRead more
Proceeds to support both bluebird bio and 2seventy bio’s pipeline of novel cell therapy programs Business separation of bluebird and 2seventy expected to be completed in October 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2021-- bluebird bio, Inc.Read more